This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Google Scholar
Right arrow Articles by Venhoff, A. C.
Right arrow Articles by Venhoff, N.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Venhoff, A. C.
Right arrow Articles by Venhoff, N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2009, p. 2748-2751, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.00364-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Mitochondrial DNA Depletion in Rat Liver Induced by Fosalvudine Tidoxil, a Novel Nucleoside Reverse Transcriptase Inhibitor Prodrug{triangledown}

Ana C. Venhoff,1 Dirk Lebrecht,1 Frank U. Reuss,2 Brigitte Heckl-Östreicher,2 Roland Wehr,2 Ulrich A. Walker,3* and Nils Venhoff1

University Hospital, Rheumatology, Freiburg, Germany,1 Heidelberg Pharma AG, Ladenburg, Germany,2 Felix-Platter Spital, Rheumatology, Basel, Switzerland3

Received 17 March 2009/ Returned for modification 16 April 2009/ Accepted 30 April 2009

Fosalvudine tidoxil is a prodrug derived from the nucleoside reverse transcriptase inhibitor 3-deoxy-3-fluorothymidine (FLT; alovudine). FLT effectively inhibits resistant human immunodeficiency virus type 1, but its clinical development was stopped due to bone marrow and liver toxicity. In this study, we examined the long-term in vivo effects of fosalvudine tidoxil on the mitochondrial DNA (mtDNA) contents in rats. Sprague-Dawley rats received fosalvudine tidoxil (15, 40, or 100 mg/kg of body weight/day) by oral gavage during a period of 8 weeks. Didanosine (100 mg/kg/day) was used as a positive control for mitochondrial toxicity. mtDNA levels in liver, gastrocnemius muscle, sciatic nerve, and inguinal fat pad tissues were quantified by real-time PCR. In hepatic mitochondria, fosalvudine tidoxil induced significant mtDNA depletion. At doses of 15, 40, and 100 mg/kg, the mean hepatic mtDNA values were 62, 64, and 47% of control values, respectively. Rats exposed to 100 mg/kg of fosalvudine tidoxil, unlike all other groups, had slightly elevated levels of glutamate pyruvate transaminase in sera. Didanosine induced a loss of mtDNA (to 48% of the control level) similar to that induced by fosalvudine tidoxil. mtDNA levels in skeletal, neural, and adipose tissues in the negative control and treatment groups were similar. Our results suggest that fosalvudine tidoxil induces mitochondrial hepatotoxicity and that this effect warrants scrutiny in clinical trials.

* Corresponding author. Mailing address: Basel University, Dept. of Rheumatology, Burgfelderstr. 101, CH 4012 Basel, Switzerland. Phone: 41-61-3264222. Fax: 41-61-3264018. E-mail: ulrich.walker{at}fps-basel.ch

{triangledown} Published ahead of print on 11 May 2009.

Antimicrobial Agents and Chemotherapy, July 2009, p. 2748-2751, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.00364-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»